-
分化型甲状腺癌(differentiated thyroid cancer,DTC)是内分泌系统中一种最常见的恶性肿瘤,分为乳头状甲状腺癌和滤泡状甲状腺癌。随着人们对健康要求的逐步提高以及医学检查技术的进步,DTC已经迅速成为发病率增长最快速的恶性肿瘤之一[1-2],多数患者预后良好,但有少数患者发生骨转移后其10年生存率只有14%~21%[3],患者生活质量也随之下降。
分化型甲状腺癌骨转移大剂量131I治疗后出现重度骨髓抑制一例
A case of severe bone marrow inhibition in the treatment of differentiated thyroid cancer by radionuclide 131I
-
摘要: 笔者报道了一例131I治疗分化型甲状腺癌(DTC)骨转移出现重度骨髓抑制的病例,从临床诊断、骨髓造血系统变化、治疗过程是否规范等方面分析该病例特点,并通过文献复习加深了对131I诊治DTC骨转移的疗效以及骨髓造血影响的认识:131I诊治DTC骨转移的临床效果明显,但随着累积剂量的提升以及患者对131I治疗个体敏感度的不同可能会发生骨髓造血系统的白细胞或血小板一过性下降。对于广泛骨转移患者131I治疗时要高度警惕骨髓抑制的发生,要尽可能考虑累积治疗剂量的因素;尽量延长再次治疗的间隔时间;出现骨髓抑制现象时,要择期使用131I治疗。Abstract: A case of severe bone marrow inhibition in the treatment of differentiated thyroid cancer (DTC) by radionuclide 131I was reported. The characteristics of the case were analyzed based on clinical diagnosis, changes in bone marrow hematopoietic system, and whether the patient's treatment process was standardized. The therapeutic effect of radionuclide 131I in the diagnosis and treatment of DTC bone metastasis and the effect of bone marrow hematopoiesis were reviewed. Radionuclide 131I had considerable clinical effect on the diagnosis and treatment of DTC bone metastasis. However, with the increase of cumulative dose and the difference of sensitivity of patients to 131I treatment, white blood cells or platelets in the bone marrow hematopoietic system may decrease. For the treatment of 131I patients with extensive bone metastasis, the occurrence of bone marrow inhibition should be on highly alert and the cumulative treatment dose should be considered. The interval between retreatment should be maximized. When bone marrow inhibition occurs in patients with extensive bone metastasis, 131I treatment should be used selectively.
-
Key words:
-
[1] Osorio M, Moubayed SP, Su H, et al. Systematic review of site distribution of bone metastases in differentiated thyroid cancer[J]. Head Neck, 2017, 39(4): 812−818. DOI: 10.1002/hed.24655 [2] Nakayama R, Horiuchi K, Susa M, et al. Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases[J]. Jpn J Clin Oncol, 2014, 44(10): 918−925. DOI: 10.1093/jjco/hyu099 [3] Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma[J]. Endocr Relat Cancer, 2008, 15(1): 37−49. DOI: 10.1677/ERC−07−0229 [4] Sobrinho-Simões M, Eloy C, Magalhães J, et al. Follicular thyroid carcinoma[J]. Mod Pathol, 2011, 24 Suppl 2: S10−18. DOI: 10.1038/modpathol.2010.133 [5] 寇天雷, 李杰. 以骨转移为首发症状的甲状腺滤泡癌病理特征分析[J]. 解放军医学院学报, 2015, 36(2): 130−132. DOI: 10.3969/j.issn.2095−5227.2015.02.010
Kou TL, Li J. Pathological features of follicular thyroid carcinoma with bone metastasis as the first symptom[J]. Acad J Chin PLA Med Sch, 2015, 36(2): 130−132. DOI: 10.3969/j.issn.2095−5227.2015.02.010[6] 王秋, 王治国, 张国旭, 等. 碘131治疗69例分化型甲状腺癌的临床观察[J]. 辽宁医学杂志, 2015, 29(1): 55−56
Wang Q, Wang ZG, Zhang GX, et al. Clinical observation of iodine 131 in the treatment of 69 patients with differentiated thyroid cancer[J]. Med J Liaoning, 2015, 29(1): 55−56[7] Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer[J]. Am J Roentgenol Radium Ther Nucl Med, 1962, 87: 171−182. [8] Thies ED, Tanase K, Maeder U, et al. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(12): 2281−2290. DOI: 10.1007/s00259−014−2851−2